Jane Armitage Nuffield Department of Population Health, University of Oxford, Oxford
PROMIS-HFpEF, the largest prospective multinational study ever conducted to assess the prevalence of coronary microvascular dysfunction (CMD) in HFpEF patients, demonstrates that CMD is associated with systemic endothelial dysfunction, heart failure severity, and myocardial dysfunction. Hence, CMD may be a composite risk marker and a potential therapeutic target in HFpEF. Carolyn S.P. Lam reports on the results of the PROMIS-HFpEF trial at ESC18 Congress.